Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)

Prophylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust p...

Full description

Saved in:
Bibliographic Details
Main Authors: Society of Gynecologic Oncology, Chinese Medical Association, Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association, Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association, Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association, National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation, Committee on Cervical Cancer, China Anti-Cancer Association, Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care
Format: Article
Language:zho
Published: Editorial Office of Medical Journal of Peking Union Medical College Hospital 2025-03-01
Series:Xiehe Yixue Zazhi
Subjects:
Online Access:https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2025-0246
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849738425355206656
author Society of Gynecologic Oncology, Chinese Medical Association
Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association
Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association
Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association
National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation
Committee on Cervical Cancer, China Anti-Cancer Association
Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care
author_facet Society of Gynecologic Oncology, Chinese Medical Association
Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association
Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association
Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association
National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation
Committee on Cervical Cancer, China Anti-Cancer Association
Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care
author_sort Society of Gynecologic Oncology, Chinese Medical Association
collection DOAJ
description Prophylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust protective efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years, with a focus on girls aged 9-14 years.Additionally, vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender-neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high-risk and special populations, including individuals with HPV infection or cytological abnormalities, those with a history of HPV-related lesions, genetically susceptible populations, individuals with high-risk lifestyle behaviors associated with cervical cancer, and immunocompromised patients.Regular cervical cancer screening remains essential post-vaccination.
format Article
id doaj-art-64e8ef19812e4278978c00207fe8f524
institution DOAJ
issn 1674-9081
language zho
publishDate 2025-03-01
publisher Editorial Office of Medical Journal of Peking Union Medical College Hospital
record_format Article
series Xiehe Yixue Zazhi
spelling doaj-art-64e8ef19812e4278978c00207fe8f5242025-08-20T03:06:36ZzhoEditorial Office of Medical Journal of Peking Union Medical College HospitalXiehe Yixue Zazhi1674-90812025-03-0116235036010.12290/xhyxzz.2025-0246Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)Society of Gynecologic Oncology, Chinese Medical AssociationBranch of Colposcopy and Cervical Pathology, China Healthy Birth Science AssociationProfessional Committee on Cancer Prevention and Control, Chinese Preventive Medicine AssociationSpecialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research AssociationNational Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer FoundationCommittee on Cervical Cancer, China Anti-Cancer AssociationBranch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health CareProphylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust protective efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years, with a focus on girls aged 9-14 years.Additionally, vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender-neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high-risk and special populations, including individuals with HPV infection or cytological abnormalities, those with a history of HPV-related lesions, genetically susceptible populations, individuals with high-risk lifestyle behaviors associated with cervical cancer, and immunocompromised patients.Regular cervical cancer screening remains essential post-vaccination.https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2025-0246human papilloma virusvaccinesclinical applicationhigh-riskspecial populations
spellingShingle Society of Gynecologic Oncology, Chinese Medical Association
Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association
Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association
Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association
National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation
Committee on Cervical Cancer, China Anti-Cancer Association
Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care
Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
Xiehe Yixue Zazhi
human papilloma virus
vaccines
clinical application
high-risk
special populations
title Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
title_full Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
title_fullStr Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
title_full_unstemmed Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
title_short Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)
title_sort preventive human papilloma virus vaccine guidelines for clinical use in china 2025 edition
topic human papilloma virus
vaccines
clinical application
high-risk
special populations
url https://xhyxzz.pumch.cn/article/doi/10.12290/xhyxzz.2025-0246
work_keys_str_mv AT societyofgynecologiconcologychinesemedicalassociation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT branchofcolposcopyandcervicalpathologychinahealthybirthscienceassociation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT professionalcommitteeoncancerpreventionandcontrolchinesepreventivemedicineassociation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT specializedcommitteeoncervicalcancerpreventionandcontrolresearchchinamaternalandchildhealthresearchassociation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT nationalcollaborativegroupforcervicalcancerpreventionandtreatmentchinacancerfoundation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT committeeoncervicalcancerchinaanticancerassociation preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition
AT branchofobstetricandgynecologicalhealthmedicinechinainternationalexchangeandpromotiveassociationformedicalandhealthcare preventivehumanpapillomavirusvaccineguidelinesforclinicaluseinchina2025edition